SCHEDULE 13G/A: BlackRock Discloses 13.2% Stake in Integra LifeSciences Holdings Corp

BlackRock, Inc. has filed an Amendment No. 17 to Schedule 13G, reporting a 13.2% beneficial ownership stake in Integra LifeSciences Holdings Corp, totaling 10,282,705 common shares as of June 30, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 17 to Schedule 13G concerning its beneficial ownership in Integra LifeSciences Holdings Corp.
• As of June 30, 2025, BlackRock, Inc. beneficially owns 10,282,705 shares of Integra LifeSciences Holdings Corp common stock.
• This ownership represents 13.2% of the total outstanding common stock of Integra LifeSciences Holdings Corp.
• BlackRock, Inc. holds sole voting power over 10,115,629 shares and sole dispositive power over 10,282,705 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• iShares Core S&P Small-Cap ETF and BlackRock Fund Advisors are identified as entities within BlackRock's structure that beneficially own more than 5% of the common stock.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. A large institutional investor maintaining a significant stake is generally a positive signal, but the document itself is purely factual disclosure without explicit positive or negative commentary on the issuer's performance.

Positives

• BlackRock, a major institutional investor, maintains a significant stake (13.2%) in Integra LifeSciences, indicating continued investment interest.
• The holding is for investment purposes in the ordinary course of business, not for control, suggesting a stable, long-term investment perspective from BlackRock.

Future Outlook

This Schedule 13G filing primarily reports current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or BlackRock's future investment intentions beyond the statement that shares are held in the ordinary course of business.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing reflects a significant passive investment by a major asset manager in a healthcare company, which is a common occurrence in the financial industry. It does not provide specific insights into broader industry trends or competitive dynamics beyond indicating BlackRock's continued interest in the healthcare sector through its investment in Integra LifeSciences.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a disclosure of beneficial ownership by a large institutional investor. It does not provide financial results or operational metrics for Integra LifeSciences that would allow for a direct comparison to industry standards or specific comparable companies/projects.
• The filing confirms BlackRock's role as a significant passive shareholder, a common practice for large asset managers like Vanguard, State Street, or Fidelity, who also hold substantial stakes across various publicly traded companies.

Stakeholder Impact

• Shareholders: Provides transparency on a major institutional investor's stake, which can influence market perception.
• Management: Awareness of a significant passive shareholder.

Next Steps

• No specific future actions or milestones for Integra LifeSciences are mentioned in this filing. BlackRock's next steps would involve continued monitoring of its investment.

Key Dates

Keywords

BlackRock, Integra LifeSciences Holdings Corp, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management, Healthcare, Medical Devices